Читать книгу Transporters and Drug-Metabolizing Enzymes in Drug Toxicity - Albert P. Li - Страница 54

Cerivastatin belongs to a class of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors commonly known as statins. Statins are one of the most prescribed drugs indicated for the lowering of plasma cholesterol. Cerivastatin was introduced by Bayer into the U.S. market in June 1997 and was withdrawn in August 2001 due to 31 deaths due to rhabdomyolysis [48–53]. Cerivastatin was introduced to compete with an existing statin, atorvastatin. Statins are commonly coadministered with fibrates for the treatment of patients with mixed hyperlipidemia [54]. Pharmacokinetic drug interactions between cerivastatin and fibrates, leading to elevated plasma levels of cerivastatin, is believed to be the major cause of rhabdomyolysis.